墨西哥科阿韦拉州 COVID-19 患者死亡的临床特征和合并症。
Clinical characteristics and comorbidities associated with mortality in patients with COVID-19 in Coahuila (Mexico).
机构信息
Secretaría de Salud del Estado de Coahuila de Zaragoza, Coahuila de Zaragoza, Mexico.
Secretaría de Salud del Estado de Coahuila de Zaragoza, Coahuila de Zaragoza, Mexico.
出版信息
Rev Clin Esp (Barc). 2022 May;222(5):288-292. doi: 10.1016/j.rceng.2020.12.007. Epub 2021 Oct 5.
Abstract
BACKGROUND AND OBJECTIVE
This study aims to describe the characteristics of patients with COVID-19 in a state in northern Mexico and establish the comorbidities associated with mortality.
METHODS
Patients with COVID-19, divided into survivors and non-survivors, were analyzed. The data were analyzed using the chi-square test, Student's t-test, and Cox's regression model.
RESULTS
A total of 17,479 patients were included and mortality rate of 6.3% was reported. Age over 60 years (HR = 8.04; 95%CI 7.03-9.19), diabetes (HR = 1.63; 95%CI 1.40-1.89), high blood pressure (HR = 1.48; 95%CI 1.28-1.72), obesity (HR = 1.37; 95%CI 1.18-1.60) and chronic kidney disease (HR = 2.06; 95%CI 1.64-2.59) were significantly associated with mortality.
CONCLUSIONS
Diabetes, high blood pressure, obesity, and chronic kidney disease increased mortality among patients with COVID-19 in the population of Coahuila, Mexico. The factor that most contributed to risk of death was age over 60 years.
摘要
背景与目的
本研究旨在描述墨西哥北部一州 COVID-19 患者的特征，并确定与死亡率相关的合并症。
方法
对 COVID-19 患者进行分析，分为幸存者和非幸存者。使用卡方检验、学生 t 检验和 Cox 回归模型对数据进行分析。
结果
共纳入 17479 例患者，报告死亡率为 6.3%。60 岁以上（HR=8.04；95%CI 7.03-9.19）、糖尿病（HR=1.63；95%CI 1.40-1.89）、高血压（HR=1.48；95%CI 1.28-1.72）、肥胖（HR=1.37；95%CI 1.18-1.60）和慢性肾脏病（HR=2.06；95%CI 1.64-2.59）与死亡率显著相关。
结论
糖尿病、高血压、肥胖和慢性肾脏病增加了墨西哥科阿韦拉州 COVID-19 患者的死亡率。导致死亡风险最大的因素是 60 岁以上的年龄。
相似文献
1
Clinical characteristics and comorbidities associated with mortality in patients with COVID-19 in Coahuila (Mexico).墨西哥科阿韦拉州 COVID-19 患者死亡的临床特征和合并症。
Rev Clin Esp (Barc). 2022 May;222(5):288-292. doi: 10.1016/j.rceng.2020.12.007. Epub 2021 Oct 5.
2
[Clinical characteristics and comorbidities associated with mortality in patients with COVID-19 in Coahuila (Mexico)].[墨西哥科阿韦拉州新冠肺炎患者与死亡相关的临床特征及合并症]
Rev Clin Esp. 2022 May;222(5):288-292. doi: 10.1016/j.rce.2020.12.006. Epub 2021 Jan 20.
3
Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico.墨西哥大型数据集内 COVID-19 患者的临床特征和死亡风险因素。
Ann Epidemiol. 2020 Dec;52:93-98.e2. doi: 10.1016/j.annepidem.2020.08.005. Epub 2020 Aug 14.
4
Chronic comorbidities and clinical outcomes in patients with and without COVID-19: a large population-based study using national administrative healthcare open data of Mexico.患有和未患有 COVID-19 的患者的慢性合并症和临床结局：利用墨西哥国家行政医疗保健公开数据进行的一项大型基于人群的研究。
Intern Emerg Med. 2021 Sep;16(6):1507-1517. doi: 10.1007/s11739-020-02597-5. Epub 2021 Jan 7.
5
Hypertension, Diabetes and Obesity, Major Risk Factors for Death in Patients with COVID-19 in Mexico.高血压、糖尿病和肥胖症是墨西哥 COVID-19 患者死亡的主要危险因素。
Arch Med Res. 2021 May;52(4):443-449. doi: 10.1016/j.arcmed.2020.12.002. Epub 2020 Dec 16.
6
Clinical characteristics and mortality risk factors in patients aged less than 18 years with COVID-19 in Mexico and Mexico City.墨西哥和墨西哥城 18 岁以下 COVID-19 患者的临床特征和死亡风险因素。
An Pediatr (Engl Ed). 2022 Aug;97(2):119-128. doi: 10.1016/j.anpede.2022.03.001. Epub 2022 Mar 11.
7
Health and Institutional Risk Factors of COVID-19 Mortality in Mexico, 2020.墨西哥 2020 年 COVID-19 死亡率的健康和机构风险因素。
Am J Prev Med. 2021 Apr;60(4):471-477. doi: 10.1016/j.amepre.2020.10.015. Epub 2020 Dec 9.
8
Risk factors associated with COVID-19 mortality in Mexico.墨西哥与 COVID-19 死亡率相关的风险因素。
Gac Med Mex. 2024;160(1):9-16. doi: 10.24875/GMM.M24000844.
9
Factors associated with death in children with COVID-19 in Mexico.墨西哥 COVID-19 患儿死亡的相关因素。
Gac Med Mex. 2020;156(6):516-522. doi: 10.24875/GMM.M21000478.
10
Obesity is a strong risk factor for short-term mortality and adverse outcomes in Mexican patients with COVID-19: a national observational study.肥胖是墨西哥新冠肺炎患者短期死亡率和不良结局的一个重要风险因素：一项全国性观察性研究。
Epidemiol Infect. 2021 Apr 29;149:e109. doi: 10.1017/S0950268821001023.
引用本文的文献
1
Use of telephone calls to manage glycemic control at Mexico's northern border.利用电话管理墨西哥北部边境地区的血糖控制。
Front Endocrinol (Lausanne). 2025 Apr 10;16:1420244. doi: 10.3389/fendo.2025.1420244. eCollection 2025.
2
The Impact of Low Serum Magnesium Levels on COVID-19 Severity and Potential Therapeutic Benefits of Magnesium Supplementation: A Systematic Review.低血清镁水平对新冠病毒疾病严重程度的影响及补充镁的潜在治疗益处：一项系统评价
Cureus. 2025 Jan 8;17(1):e77118. doi: 10.7759/cureus.77118. eCollection 2025 Jan.
3
COVID-19 epidemic investigation study of a follow-up cohort of patients with diabetic kidney disease.COVID-19 疫情对糖尿病肾病患者随访队列的影响调查研究。
Front Cell Infect Microbiol. 2024 Aug 20;14:1388260. doi: 10.3389/fcimb.2024.1388260. eCollection 2024.
4
Spatial Survival Model for COVID-19 in México.墨西哥新冠肺炎的空间生存模型
Healthcare (Basel). 2024 Jan 24;12(3):306. doi: 10.3390/healthcare12030306.
5
Risk Factors for Mortality of Hospitalized Adult Patients with COVID-19 Pneumonia: A Two-Year Cohort Study in a Private Tertiary Care Center in Mexico.墨西哥一家私立三级护理中心的一项为期两年的队列研究：住院成人 COVID-19 肺炎患者死亡的危险因素。
Int J Environ Res Public Health. 2023 Mar 2;20(5):4450. doi: 10.3390/ijerph20054450.
6
Extreme obesity is a strong predictor for in-hospital mortality and the prevalence of long-COVID in severe COVID-19 patients with acute respiratory distress syndrome.极度肥胖是急性呼吸窘迫综合征重症 COVID-19 患者住院死亡率和长新冠患病率的一个强有力预测指标。
Sci Rep. 2022 Nov 1;12(1):18418. doi: 10.1038/s41598-022-22107-1.
7
Risk Factors Associated with Mortality in Hospitalized Patients with COVID-19 during the Omicron Wave in Brazil.巴西奥密克戎毒株流行期间新冠肺炎住院患者死亡相关危险因素
Bioengineering (Basel). 2022 Oct 20;9(10):584. doi: 10.3390/bioengineering9100584.
8
The relevance of magnesium homeostasis in COVID-19.镁稳态与 COVID-19 的相关性。
Eur J Nutr. 2022 Mar;61(2):625-636. doi: 10.1007/s00394-021-02704-y. Epub 2021 Oct 23.
9
Obesity as a Risk Factor for Severe COVID-19 and Complications: A Review.肥胖作为 COVID-19 重症和并发症的风险因素：综述。
Cells. 2021 Apr 17;10(4):933. doi: 10.3390/cells10040933.
本文引用的文献
1
[Epidemiology of COVID-19 in Mexico: from the 27th of February to the 30th of April 2020].[墨西哥2019冠状病毒病流行病学：2020年2月27日至4月30日]
Rev Clin Esp. 2020 Nov;220(8):463-471. doi: 10.1016/j.rce.2020.05.007. Epub 2020 May 27.
2
Comorbidity and its Impact on Patients with COVID-19.合并症及其对COVID-19患者的影响。
SN Compr Clin Med. 2020;2(8):1069-1076. doi: 10.1007/s42399-020-00363-4. Epub 2020 Jun 25.
3
Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico.墨西哥大型数据集内 COVID-19 患者的临床特征和死亡风险因素。
Ann Epidemiol. 2020 Dec;52:93-98.e2. doi: 10.1016/j.annepidem.2020.08.005. Epub 2020 Aug 14.
4
Risk factors for mortality among COVID-19 patients.COVID-19 患者死亡的风险因素。
Diabetes Res Clin Pract. 2020 Aug;166:108293. doi: 10.1016/j.diabres.2020.108293. Epub 2020 Jul 3.
5
IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT.墨西哥新冠病毒检测呈阳性患者中合并症的影响：一项全国队列的回顾性分析
Rev Invest Clin. 2020;72(3):151-158. doi: 10.24875/RIC.20000207.
6
Mortality and survival of COVID-19.COVID-19 的死亡率和生存率。
Epidemiol Infect. 2020 Jun 25;148:e123. doi: 10.1017/S0950268820001405.
7
Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis.感染SARS-CoV2患者的合并症患病率及死亡病例：一项系统评价与荟萃分析。
Rev Inst Med Trop Sao Paulo. 2020 Jun 22;62:e43. doi: 10.1590/S1678-9946202062043. eCollection 2020.
8
Ethnic disparities in COVID-19 mortality: are comorbidities to blame?新冠病毒疾病（COVID-19）死亡率中的种族差异：应归咎于合并症吗？
Lancet. 2020 Jul 4;396(10243):22. doi: 10.1016/S0140-6736(20)31423-9. Epub 2020 Jun 19.
9
[Coronavirus disease 2019 (COVID-19) in Latin America: Role of primary care in preparedness and response].拉丁美洲的2019冠状病毒病（COVID-19）：初级保健在防范与应对中的作用
Aten Primaria. 2020 Jun-Jul;52(6):369-372. doi: 10.1016/j.aprim.2020.04.001. Epub 2020 Apr 17.
10
Association between age and clinical characteristics and outcomes of COVID-19.年龄与 COVID-19 的临床特征和结局的关系。
Eur Respir J. 2020 May 27;55(5). doi: 10.1183/13993003.01112-2020. Print 2020 May.
Zotero 插件